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Purpose
Purpose of this prospective, multi-institutional Phase I
clinical study was to investigate whether MRI-guided
transurethral ultrasound ablation (MR-TULSA), a novel
minimally-invasive technology to treat organ-confined
prostate cancer (PCa), is safe, feasible and effective. It
employs directional plane-wave high-intensity ultra-
sound, which ablates prostate tissue using real-time
thermometry with active temperature feedback control.
Methods
Enrolled were 30 patients with biopsy-proven, low-risk
prostate cancer (age ≥ 65y, T1c/T2a, PSA ≤ 10ng/ml,
Gleason 6 (3+3)). Whole-gland prostate ablation was per-
formed with MR-TULSA using the PAD-105 (Profound
Medical Inc., Canada) and a 3T MRI (Siemens, Germany)
in one single treatment session under general anaesthesia
and 3D active MR-thermometry feedback control.
Contrast-enhanced MRI (CE-MRI) immediately following
the ablation and at 12 months confirmed thermal
coagulation.
Results
There were no intraoperative complications with normal
micturition resuming after catheter removal. Median
(range) treatment time and prostate volume were 36
(24– 61) min and 44 (21– 95) ml, respectively. Maximum
temperature during treatment depicted a continuous
region of heating shaped accurately to the prostate within
0.1 ± 1.3 mm, with average over- and under- targeted
volumes of 0.8 and 1.0 ml, respectively. Regions of acute
cell kill on CE-MRI correlated well with treated volume
on MR-thermometry. Successful treatment was further
confirmed by a median PSA decrease from 5.35 to 0.70
ng/ml at 1 month (n=29), remaining stable to 0.65 ng/ml
at 6 months (n=16).
Conclusion
Phase I results show that MR-TULSA represents a mini-
mally-invasive treatment option for safe, effective and
accurate whole-gland thermal ablation of organ-confined
prostate cancer.
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